# Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

> **NCT02918123** · PHASE1 · UNKNOWN · sponsor: **Kang Stem Biotech Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** FURESTEM-CD Inj.

## Key facts

- **NCT ID:** NCT02918123
- **Lead sponsor:** Kang Stem Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-17
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02918123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02918123, "Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02918123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*